Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, announced the appointment of Ken Song, M.D., as its new president, chief executive officer and director. He most recently was co-founder and chief executive officer of Ariosa Diagnostics, which was acquired by Roche in 2015 for $625 million.
"Ken's proven leadership, track record and broad expertise serving the life science communi...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In